Rangering i aksjer
#25853
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aksjekurs
$15.31
Sist synkronisert: 2024-02-29
Handel Icosavax, Inc. (ICVX)
Pris ICVX pris med markedsverdi på B
Markedsverdi av Icosavax, Inc.(ICVX)
Markedsverdi: $45.70M
Per August 2026 har Icosavax, Inc. en markedsverdi på $45.70M. Dette gjør Icosavax, Inc. til det 25853rd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Icosavax, Inc. fra 2021 til 2026
ICVX sammenlignet med topp 5 mest populære stocks
| Pris på ICVX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.257T
|
+11,501,961.75%
|
|
|
|
|
$4.599T
|
+10,061,812.56%
|
|
|
|
|
$4.107T
|
+8,985,159.26%
|
|
|
|
|
$3.577T
|
+7,826,978.55%
|
|
|
|
|
$2.807T
|
+6,142,321.87%
|
